Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04153188 · ClinicalTrials.gov registry record · Phase 4
Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
A Phase 4 study of Erythematotelangiectatic Rosacea, sponsored by Candela Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 2
- Study locations
NCT04153188 is a Phase 4 study of Erythematotelangiectatic Rosacea that has completed, run by Candela Corporation. The registered enrollment target is 34 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT04153188, a Phase 4 study of Erythematotelangiectatic Rosacea, has completed, sponsored by Candela Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe erythematotelangiectatic rosacea.
Conditions Studied
Interventions
- DEVICE The Vbeam® Prima System
- DRUG Oxymetazoline HCL 1% Cream
Study Locations (2)
North Carolina
- Dermatology, Laser & Vein Specialists of the Carolinas - Charlotte
Texas
- Dermatology & Laser Surgery Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04153188
The ClinicalTrials.gov registry entry for NCT04153188 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Candela Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Erythematotelangiectatic Rosacea appearing as the primary indexed condition, and to 2 interventions - of which The Vbeam® Prima System is the first listed.
NCT04153188 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT04153188 about?
NCT04153188 is a clinical study titled "Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea". This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe erythematotelangiectatic rosacea.
What is the current status of trial NCT04153188?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2019-01-15. Estimated completion is 2021-01-05.
What conditions does trial NCT04153188 study?
This clinical trial studies the following conditions: Erythematotelangiectatic Rosacea.
What interventions are being tested in trial NCT04153188?
The interventions under investigation include: The Vbeam® Prima System (DEVICE), Oxymetazoline HCL 1% Cream (DRUG).
Who is sponsoring clinical trial NCT04153188?
This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04153188 being conducted?
This trial has 2 study locations across North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erythematotelangiectatic Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.